<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;C02K&quot;,&quot;href&quot;:&quot;atc/C02K.md&quot;},{&quot;label&quot;:&quot;ketanserin&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;Ketanserin_Michiels1988_reference&quot;,&quot;label&quot;:&quot;Michiels_1988_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_ketanserin/Ketanserin_Michiels1988_reference.md&quot;,&quot;status&quot;:&quot;reviewed \u2014 candidate&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Ketanserin_Hanff2005_reference&quot;,&quot;label&quot;:&quot;Hanff_2005_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_ketanserin/Ketanserin_Hanff2005_reference.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Ketanserin_Trenk1983_reference&quot;,&quot;label&quot;:&quot;Trenk_1983_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_ketanserin/Ketanserin_Trenk1983_reference.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false}]"></div>

# ketanserin

- **generic name:** ketanserin
- **ATC codes:** `C02KD01`
- **DrugBank:** [DB12465](https://go.drugbank.com/drugs/DB12465) · **PubChem:** [CID 3822](https://pubchem.ncbi.nlm.nih.gov/compound/3822)
- **molar mass:** 395.434 g/mol (C22H22FN3O3) — DrugBank
- **groups:** investigational

## About

Ketanserin is a serotonin antagonist that has been used as an antihypertensive drug and to treat chronic skin ulcers. It is currently considered investigational and is not an approved medicine in the European Union.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q415997](https://www.wikidata.org/wiki/Q415997) and the WHO ATC classification; not checked by a person.</small>

## Molecules and molar masses

> The molar mass each model uses to convert mass to molar concentration and to form a metabolite molecule for molecule. Looked up, never estimated: DrugBank for the drug, the paper's own value or the PubChem entry matched to the paper's name for a metabolite.

| molecule | role | molar mass (g/mol) | formula | source | PubChem | records |
|---|---|---|---|---|---|---|
| ketanserin | parent | 395.434 | C22H22FN3O3 | DrugBank | [3822](https://pubchem.ncbi.nlm.nih.gov/compound/3822) | Hanff_2005, Kurowski_1985, Michiels_1988, Trenk_1983 |
| ketanserinol | metabolite | 397.45 | C22H24FN3O3 | PubChem | [156394](https://pubchem.ncbi.nlm.nih.gov/compound/156394) | Kurowski_1985 |

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-28 02:18 | 14:24 | 1/1/2 | 1/0/0 | 0/0/0 | 126,206/25,671 | ollama / qwen3.8:27b-mtp-q8_0 | 2 | 1/1 | 2/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">reviewed — candidate</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (partly confirmed, agreement 0.778). The first reading is what the record holds.">cross-check: partial</span> <span class="pk-badge pk-badge--species" title="Animal study (rat), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">rat</span> | [Michiels_1988_reference](drugs/drug_ketanserin/Ketanserin_Michiels1988_reference.md) | ▶ model + simulator | 1-compartment, IV | 4 | Michiels M et al., Pharmacokinetics and tissue distributio…, Arzneimittel-Forschung (1988) | — |
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.125). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: unreported model parameter default(s): ka</sub><br><sub>route_to: `scholar`</sub> | [Hanff_2005_reference](drugs/drug_ketanserin/Ketanserin_Hanff2005_reference.md) | ▶ model + simulator | 1-compartment, oral | 2 | Hanff LM et al., Population pharmacokinetics of ketanser…, Fundamental & clinical phar… (2005) | [10.1111/j.1472-8206.2005.00354.x](https://doi.org/10.1111/j.1472-8206.2005.00354.x) |
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.214). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: T6_deviations</sub><br><sub>route_to: `engineer`</sub> | [Trenk_1983_reference](drugs/drug_ketanserin/Ketanserin_Trenk1983_reference.md) | ▶ model + simulator | 1-compartment, IV | 4 | Trenk D et al., Pharmacokinetics and pharmacodynamics o…, Journal of cardiovascular p… (1983) | [10.1097/00005344-198311000-00018](https://doi.org/10.1097/00005344-198311000-00018) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.087). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: no distribution volume and no clearance/elimination — not a compartmental popPK…</sub><br><sub>route_to: `human_review`</sub> | [Kurowski_1985_reference](drugs/drug_ketanserin/Ketanserin_Kurowski1985_reference.md) | — | parent + metabolite (no model) | 6 | Kurowski M, Bioavailability and pharmacokinetics of…, European journal of clinica… (1985) | [10.1007/BF00544359](https://doi.org/10.1007/BF00544359) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> | [Hattori_2017_EFS_induced_contraction_potentiation_percent_of_80_mM_KCl_contraction](drugs/drug_ketanserin/pd_Hattori_2017_EFS_induced_contraction_potentiation_percent_of.md) | EFS-induced contraction potentiation (percent of 80 mM KCl contraction) ← alpha-methyl-serotonin (alpha-Me-5-HT) · direct Emax (saturable) effect | — | Hattori T et al., Ketanserin and Naftopidil Enhance the P…, International neurourology… (2017) | [10.5213/inj.1732758.379](https://doi.org/10.5213/inj.1732758.379) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=ketanserin) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|

<sub>Actors without a tissue in the table: HTR2A (inverse agonist).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 212 matched, 24 returned
- **screened:** 5  ·  **relevant:** 5
- **records:** 4  ·  extracted 1  ·  needs_review 2  ·  rejected 1  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Full text wanted

_8 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Aljuffali_2012.pdf` | Aljuffali IA et al., Pharmacokinetic assessment of ketanseri…, Journal of veterinary pharm… (2012) | popPK | 10 | [10.1111/j.1365-2885.2011.01346.x](https://doi.org/10.1111/j.1365-2885.2011.01346.x) | [22091605](https://pubmed.ncbi.nlm.nih.gov/22091605) | The study reports quantitative pharmacokinetic parameters (CL, Vss, t1/2) for ketanserin in horses directly in the text. |
| `Hanff_2005.pdf` | Hanff LM et al., Population pharmacokinetics of ketanser…, Fundamental & clinical phar… (2005) | popPK | 10 | [10.1111/j.1472-8206.2005.00354.x](https://doi.org/10.1111/j.1472-8206.2005.00354.x) | [16176338](https://pubmed.ncbi.nlm.nih.gov/16176338) | The paper reports specific population pharmacokinetic parameters (Cl(m) and V1) for ketanserin in the abstract text. |
| `Michiels_1988.pdf` | Michiels M et al., Pharmacokinetics and tissue distributio…, Arzneimittel-Forschung (1988) | popPK | 10 | not captured | [3178917](https://pubmed.ncbi.nlm.nih.gov/3178917) | The paper reports quantitative pharmacokinetic parameters (clearance, volume of distribution, half-life) for ketanserin in rats and dogs directly in the text. |
| `Trenk_1983.pdf` | Trenk D et al., Pharmacokinetics and pharmacodynamics o…, Journal of cardiovascular p… (1983) | popPK | 10 | [10.1097/00005344-198311000-00018](https://doi.org/10.1097/00005344-198311000-00018) | [6196551](https://pubmed.ncbi.nlm.nih.gov/6196551) | The paper reports quantitative PK parameters (CL, Vss, t1/2, F) for ketanserin in humans with specific numeric values present in the text. |
| `Kurowski_1985.pdf` | Kurowski M, Bioavailability and pharmacokinetics of…, European journal of clinica… (1985) | popPK | 9 | [10.1007/BF00544359](https://doi.org/10.1007/BF00544359) | [3161741](https://pubmed.ncbi.nlm.nih.gov/3161741) | The study reports quantitative PK parameters for ketanserin including half-life, AUC, and Cmax, though specific clearance and volume values are not explicitly listed in the provided text. |
| `Holze_2024.pdf` | Holze F et al., Ketanserin exhibits dose- and concentra…, European neuropsychopharmac… (2024) | pd | 5 | [10.1016/j.euroneuro.2024.07.003](https://doi.org/10.1016/j.euroneuro.2024.07.003) | [39121715](https://www.ncbi.nlm.nih.gov/pubmed/39121715) | metadata signals extractable PD data (EC50) |
| `Kaufman_1995.pdf` | Kaufman MJ et al., Serotonin 5-HT2C receptor stimulates cy…, Journal of neurochemistry (1995) | pd | 4 | [10.1046/j.1471-4159.1995.64010199.x](https://doi.org/10.1046/j.1471-4159.1995.64010199.x) | [7798914](https://www.ncbi.nlm.nih.gov/pubmed/7798914) | metadata signals extractable PD data (EC50) |
| `Zhang_1994.pdf` | Zhang ZH et al., Ketanserin inhibits depolarization-acti…, Circulation research (1994) | pd | 4 | [10.1161/01.res.75.4.711](https://doi.org/10.1161/01.res.75.4.711) | [7923617](https://www.ncbi.nlm.nih.gov/pubmed/7923617) | metadata signals extractable PD data (EC50) |

<sub>queue written 2026-09-28T02:09:51.123966+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Coenen_1988 | irrelevant | 0 | 0 | The study focuses on PET receptor binding of 18F-fluoroethylspiperone, and ketanserin is only used as a cold competitor to block S2 receptors, not as the subject drug for PK analysis. |
| popPK | Ettrup_2014 | irrelevant | 0 | 0 | The study focuses on PET imaging of a radioligand ([11C]Cimbi-36) and uses ketanserin only as a blocking agent to confirm receptor selectivity, without reporting pharmacokinetic parameters for ketanserin. |
| popPK | Finnema_2014 | irrelevant | 0 | 0 | The study is a PET imaging characterization of a radioligand where ketanserin is used only as a competitive antagonist for receptor occupancy, not as the subject drug for pharmacokinetic parameter estimation. |
| popPK | Hattori_2017 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of bladder muscle contraction using ketanserin as a receptor antagonist, and it does not report any pharmacokinetic parameters. |
| popPK | Hauser_2002 | irrelevant | 0 | 0 | The study is a pharmacodynamic investigation of ureteral motility in pigs and does not report any pharmacokinetic parameters for ketanserin. |
| PGx | Holthoewer_2013 | not_relevant | 0 | 0 | The paper focuses on the pharmacogenomic effects of P-gp deficiency on aripiprazole and ziprasidone; ketanserin is only used as a control compound and no pharmacogenomic effects on its PK/PD parameters are reported. |
| popPK | Holze_2024 | irrelevant | 0 | 0 | no_text gate: only 147 chars of text extracted (&lt; 400) |
| popPK | Ishitani_1994 | irrelevant | 0 | 0 | The paper is an in-vitro mechanistic study on phosphoinositide turnover in cultured cells, not a pharmacokinetic study, and ketanserin is only used as a non-effective control agent. |
| PD | Ishitani_1994 | not_relevant | 0 | 0 | The paper reports dose-response parameters for tryptamine, but explicitly states that ketanserin had no effect on the measured responses, providing no PD relationship or numeric parameters for ketanserin. |
| PGx | Jiang_2015 | not_relevant | 0 | 0 | The paper studies the pharmacodynamics of 5-MeO-DMT and harmaline, using ketanserin only as a receptor antagonist tool, and does not report pharmacogenomic effects on ketanserin's PK or PD parameters. |
| popPK | Kaufman_1995 | irrelevant | 0 | 0 | no_text gate: only 75 chars of text extracted (&lt; 400) |
| PD | Kaufman_1995 | not_relevant | 0 | 0 | The paper focuses on the mechanism of 5-HT2C receptor stimulation of cGMP formation in choroid plexus and does not report any pharmacodynamic or exposure-response analysis for ketanserin. |
| popPK | Kester_2003 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological characterization of isolated human prostate tissue, not a pharmacokinetic study, and ketanserin is used only as a comparative antagonist agent. |
| popPK | Ni_2004 | irrelevant | 0 | 0 | The study investigates the vasoactive properties of norfenfluramine, using ketanserin only as a pharmacological antagonist to confirm receptor involvement, rather than as the subject of a pharmacokinetic analysis. |
| PD | Ni_2004 | not_relevant | 0 | 0 | The paper reports PD parameters for (+)-norfenfluramine, not ketanserin; ketanserin is used only as a qualitative antagonist to confirm receptor mechanism. |
| popPK | Perlmutter_1991 | irrelevant | 0 | 0 | The study uses ketanserin as a competitive antagonist to validate a PET assay for spiperone binding, rather than measuring the pharmacokinetic parameters of ketanserin itself. |
| PGx | Rietjens_2012 | not_relevant | 0 | 0 | The paper discusses MDMA pharmacokinetics and pharmacodynamics, mentioning ketanserin only as a potential therapeutic agent for MDMA intoxication, without reporting any pharmacogenomic effects on ketanserin itself. |
| popPK | Santos_2022 | irrelevant | 0 | 0 | The study investigates the vasoconstrictor effects of a toad poison extract, using ketanserin only as a pharmacological tool to block 5-HT2 receptors, and reports no pharmacokinetic parameters for ketanserin. |
| PD | Santos_2022 | not_relevant | 0 | 0 | The paper investigates the pharmacodynamics of Rhinella marina toad poison, not ketanserin; ketanserin is used only as a tool compound to characterize receptor involvement. |
| popPK | Schönbächler_2002 | irrelevant | 0 | 0 | The study focuses on PET imaging of dopamine transporters using a radioligand, and ketanserin is used only as a non-specific blocking agent, not as the subject of pharmacokinetic analysis. |
| popPK | Watts_2004 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological characterization of 5-HT receptors in rat renal arteries where ketanserin is used only as a receptor antagonist, not as the subject drug for PK analysis. |
| PD | Watts_2004 | not_relevant | 3 | 2 | The paper reports qualitative antagonist shifts (3 and 10 nM) for ketanserin in an isolated tissue bath but does not provide numeric PD parameters (e.g., pA2, Ki, or full concentration-effect curves) for ketanserin itself. |
| popPK | Zhang_1994 | irrelevant | 0 | 0 | no_text gate: only 98 chars of text extracted (&lt; 400) |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-09-28 02:10 UTC</sub>
